Specialist preclinical contract research organisation (CRO) Cellomatics Biosciences has heralded the start of its next successful phase with four promotions and eight new arrivals.
Dr Shailendra Singh, CEO of Cellomatics Biosciences, comments: “Capitalising on our existing strengths and internal team expertise, we intend to further consolidate our position as a specialist Biology CRO by broadening and deepening our service offerings in 2024. With these new appointments and internal restructuring, we are poised to catapult ourselves to the next phase of our growth journey.”
Cellomatics is building on its expanding client base which now boasts over a hundred global clients, delivering approximately 320 scientific projects across all therapeutic areas of which sixty-six projects were completed in 2023 alone and a further 15 new clients added in the same financial year.
The company has enjoyed outstanding growth recently within the area of inflammation with a five-fold increase in export revenue in the last three years. Cellomatics exported to three new countries, with inflammation revenue generated for the first time in an existing market (Italy), and strong growth achieved in Singapore and USA. Shailendra said: “Overall, we have doubled our revenue over the last 2 years which has been phenomenal considering the challenging biotech funding environment.” He adds: “It’s an exciting time to be joining the Cellomatics team.”
Looking forward to the challenges ahead are Senior Bioassay Scientists Daniele Baiz and Tsemay Tse, alongside Bioassay Scientists Arun Flynn, Silvana Tivadar and Klaudia Rzepecka. Also joining the team are Thomas Cox and Huan Thompson as Associate Scientists and Mariam Al-Naseri as Laboratory Administrator.
For Daniele Baiz, it’s a return to the fold as he rejoins Cellomatics. He comments: “I am thrilled to return to Cellomatics Biosciences, a vibrant and dynamic business focused on innovative solutions, strengthened with a set of analytical skills and experience with biologics at clinical stage.
I will take the challenge of delivering novel bioassays and in vitro models of diseases to test the next generation of medicines and immuno‑oncology therapeutics.
I look forward to working in a team of talented scientists to support the success of our clients.”
Mariam Al-Naseri is at the start of her career having recently graduated from Nottingham Trent University where she gained her bachelor’s degree in pharmacology. Mariam comments: “I like Nottingham, so I decided to stay on here after my degree. I’m going to use my position here at Cellomatics to develop and grow and broaden my knowledge base.”
The four internal promotions include Pharmacology graduate, Oscar Neil, who joined Cellomatics as a Laboratory Assistant in August last year and has now been rewarded for his efforts with a promotion to Associate Scientist. Oscar comments: “What I enjoy about the work here is the variety.” He adds: “I’m a big believer in doing what you enjoy, and I really enjoy the work here.”
Katie Hudson has transitioned from Immuno-Oncology Scientist to Senior Bioassay Scientist and Alex Timmis has been promoted from Senior Bioassay Scientist to Bioassay Study Manager. Alex says: “I’m really looking forward to the challenges the new role will bring. I’ll be taking up more of a client-facing role, building on existing relationships and developing new ones as well as managing the team here to deliver what the client wants. I get a great deal of satisfaction in overseeing a project from start to finish and in being able to manage a client’s expectations.”
And finally, Dr Lara De Tomasi, has been promoted to Bioassay Study and Operations Manager from Senior Bioassay Scientist. Lara comments: “My new role will involve overseeing the smooth running of the scientific aspect of the business, managing the client projects rather than conducting them personally. The Cellomatics philosophy is built around strong client relationships and becoming a part of their extended team. This has already delivered over 60% repeat business in the last financial year. My role is to cement those relationships and ensure that projects are delivered to the highest standards.” She adds: “Clearly one of my first tasks, with the help of Alex, is overseeing the smooth transition of the promotions and the new appointees which, considering the numbers, presents its own challenges!”
Release written by Medilink Midlands Member Cellomatics Biosciences.